Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Philippine Journal of Urology ; : 70-77, 2022.
Artigo em Inglês | WPRIM | ID: wpr-962070

RESUMO

OBJECTIVE@#To evaluate the clinical benefit of Abiraterone acetate plus prednisone (AA + P) withandrogen deprivation therapy in patients with metastatic prostate cancer as a local experience in thePhilippines.@*MATERIALS AND METHODS@#The authors evaluated retrospectively a case series of seven patients receivingandrogen deprivation therapy with high-risk metastatic castration-sensitive prostate cancer (mCSPC)and metastatic castration-resistant prostate cancer (mCRPC) treated with AA + P in a tertiary hospitalfrom April 2019 to October 2020. Disease characteristics, biochemical trend, quality of life evaluationusing the European Organization for Research and Treatment of Cancer Questionnaire (EORTCQLQ-C30 v.3), and adverse events reporting using Common Terminology Criteria for Adverse Events(CTCAE) Version 5.0 were all retrieved from the medical records as outcome measures.@*RESULTS@#Analysis of 18 months period using chart review was done. Five patients showed clinicalimprovement on positive PSA response. Patients also presented with Grade 1-2 adverse events scorebased on CTCAE including hypertension, hepatotoxicity, gastrointestinal symptoms, and electrolyteimbalances. Using the EORTC QLQ-C30 v.3 showed that AA + P provided significant improvementon the overall quality of life, functioning in terms of role, emotional, cognitive and social aspectswith reasonable safety profile and minimal adverse events limited to worsening of gastrointestinalsymptoms from baseline.@*CONCLUSION@#The addition of AA + P to androgen deprivation therapy is a suitable option for bothhigh-risk mCSPC and mCRPC exhibiting a significant biochemical, functional and quality of lifeimprovement with reasonable safety profile and limited adverse events in the ‘real-world’ setting, whichis comparable with the findings in other similar studies.

2.
Philippine Journal of Urology ; : 82-87, 2019.
Artigo em Inglês | WPRIM | ID: wpr-962341

RESUMO

@#Urinary tract endometriosis is present in approximately 1% of women. Bladder endometriosis (BE) is defined as presence of endometrial glands and stroma in the detrusor muscle. Close collaboration of the urologists and gynecologists in dealing with urinary tract endometriosis is necessary in order to establish both the correct diagnostic procedure and the most adequate management. Presented here is the case of a 42-year old female, G3P3 (3003), who presented with intermittent episodes of right-sided flank pain four months post-hysterectomy. She was initially diagnosed to have a bladder tumor and underwent transurethral resection of bladder tumor. Histopathological examination of the resected specimen revealed endometriosis.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA